StreetInsider.com News Articles

Form EFFECT Cellectar Biosciences,

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586857.html

Form EFFECT Cellectar Biosciences,

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586857.html

Form 424B3 Cellectar Biosciences,

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586868.html

Form 424B3 Cellectar Biosciences,

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586868.html

Cellectar reports 79% response rate in Waldenstrom cancer study

Mon, 01 Jun 2026 08:05:30 -0400

Cellectar Biosciences Inc. (NASDAQ: CLRB) reported efficacy data from its Phase 2b CLOVER WaM clinical trial of iopofosine I 131 for treating relapsed or refractory Waldenström macroglobulinemia at the American Society of Clinical Oncology Annual Meeting.

The subset analysis examined 24 patients whose immediately prior treatment was a Bruton Tyrosine Kinase inhibitor (BTKi). The company reported a 79.2% major response rate and an 87.5% overall response rate. The median duration of response was 16 months, with 20% of patients exceeding 30 months duration of response.

The trial enrolled patients who had received greater than two prior therapies and had symptomatic disease requiring

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology An

Mon, 01 Jun 2026 08:05:00 -0400

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in
Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26

FLORHAM PARK, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Company’s Phase 2

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology An

Mon, 01 Jun 2026 08:05:00 -0400

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in
Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26

Form S-1/A Cellectar Biosciences,

Fri, 29 May 2026 08:50:00 -0400

si-local-file:///var/storage/secattach/20260529/26571229.html

Form S-1/A Cellectar Biosciences,

Fri, 29 May 2026 08:50:00 -0400

si-local-file:///var/storage/secattach/20260529/26571229.html

Form DEFA14A Cellectar Biosciences,

Thu, 28 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260528/26568884.html

Form DEFA14A Cellectar Biosciences,

Thu, 28 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260528/26568884.html

Form DEF 14A Cellectar Biosciences, For: Jul 07

Thu, 28 May 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260528/26568865.html

Form DEF 14A Cellectar Biosciences, For: Jul 07

Thu, 28 May 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260528/26568865.html

Form S-1 Cellectar Biosciences,

Tue, 19 May 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260519/26522448.html

Form S-1 Cellectar Biosciences,

Tue, 19 May 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260519/26522448.html

Form PRE 14A Cellectar Biosciences, For: May 18

Mon, 18 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260518/26514879.html

Form PRE 14A Cellectar Biosciences, For: May 18

Mon, 18 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260518/26514879.html

Form 8-K Cellectar Biosciences, For: May 17

Mon, 18 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260518/26514057.html

Form 8-K Cellectar Biosciences, For: May 17

Mon, 18 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260518/26514057.html

Ladenburg Thalmann Assumes Cellectar Biosciences (CLRB) at Buy

Fri, 15 May 2026 06:35:07 -0400

Ladenburg Thalmann analyst Kevin DeGeeter assumes coverage on Cellectar Biosciences (NASDAQ: CLRB) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Cellectar Biosciences click here. For more ratings news on Cellectar Biosciences click here.

Shares of Cellectar Biosciences closed at $3.20 yesterday.

Cellectar Biosciences (CLRB) Misses Q1 EPS by 133c

Thu, 14 May 2026 07:27:23 -0400

Cellectar Biosciences (NASDAQ: CLRB) reported Q1 EPS of ($1.33).

For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.

Form 8-K Cellectar Biosciences, For: May 14

Thu, 14 May 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260514/26489855.html

Form 8-K Cellectar Biosciences, For: May 14

Thu, 14 May 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260514/26489855.html

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 14 May 2026 07:15:00 -0400

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval

Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026

Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 14 May 2026 07:15:00 -0400

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval

Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026

Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy